Actionable news
0
All posts from Actionable news
Actionable news in RGLS: Regulus Therapeutics Inc.,

Regulus Therapeutics' HCV candidate RG-101, in combination with other antivirals, shows cure rates as high as 100% in eight weeks; shares up 11% premarket

Regulus Therapeutics (NASDAQ:RGLS) is up 11% premarket on higher-than-normal volume in response to its announcement of additional interim results from its ongoing Phase 2 development of RG-101 for the treatment of chronic hepatitis C virus (HCV) infection. The data were presented at The International Liver Congress 2016 in Barcelona, Spain.

The study was designed to assess a shortened four-week regimen of RG-101, 2 mg/kg administered via subcutaneous injection at...


More